Sweeping changes in U.S. trade policy are reshaping the pharmaceutical logistics landscape, creating unprecedented challenges for global supply chains.

With new tariffs, ranging from 10% on most imports to as high as 245% on APIs from China, manufacturers, distributors, and healthcare providers face rising costs, supply risks, and pressure to adapt quickly.

The push for onshoring essential medicines offers long-term resilience but brings immediate hurdles, including infrastructure demands and potential drug shortages. In this environment, deep expertise of duty payments and leveraging key exemptions for prototypes becomes critical to maintaining compliance and controlling costs.

Pharmaceutical companies that diversify sourcing, build inventory buffers, adopt advanced analytics, and strengthen partnerships will be best positioned to navigate these disruptions. remain resilient.

Read the full article below featuring Reynaldo Roman, Marken’s Senior Director, Regulatory Compliance, to explore strategies, exemptions, and actionable insights impacting the future of pharma logistics – and how Marken is helping clients stay ahead.